Notebook

OLD NEWS REBORN TRANS-ATLANTIC MEDITATION AIDS HONORS FROM THE FRYING PAN TO THE PHARMACY CHEMIST HONORED BRAIN-PROTECTING DRUGS OLD NEWS REBORN The wild spike in the stock price earlier this month of Rockville, Md.-based biotechnology company EntreMed Inc. was sparked by a few remarks over dinner, says the company's chairman, John Holaday. The comments came from Nobel laureate James Watson, director of the Cold Spring Harbor Laboratory on Long Island, N.Y. He was praising the work of M. Judah

The Scientist Staff
May 24, 1998

OLD NEWS REBORN
TRANS-ATLANTIC MEDITATION
AIDS HONORS
FROM THE FRYING PAN TO THE PHARMACY
CHEMIST HONORED
BRAIN-PROTECTING DRUGS OLD NEWS REBORN The wild spike in the stock price earlier this month of Rockville, Md.-based biotechnology company EntreMed Inc. was sparked by a few remarks over dinner, says the company's chairman, John Holaday. The comments came from Nobel laureate James Watson, director of the Cold Spring Harbor Laboratory on Long Island, N.Y. He was praising the work of M. Judah Folkman and colleagues at Children's Hospital in Boston, whose research has shown that protein inhibitors of angiogenesis, or blood vessel growth, cause a variety of tumors in mice to regress (H. Black, The Scientist, 12[9]:10, April 27, 1998). A New York Times reporter heard Watson's words and quoted him in a subsequent article as saying, "Judah is going to cure cancer in two years." EntreMed, which is...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?